Wavefront technology approval
This article was originally published in The Gray Sheet
Executive Summary
Shipments of Zywave II and Orbscann IIz eye diagnostic systems begin immediately upon PMA supplemental approval of the Zypotix personalised LASIK system, announced Oct. 10, building on Bausch & Lomb's Technolas 217z excimer laser platform. B&L will launch a series of TV ads for the system, approved to treat myopia up to -7 diopters and astigmatism up to -3 D (1"The Gray Sheet" Sept. 15, 2003, p. 9). Competitors include Visx and Alcon...
You may also be interested in...
B&L Looks To TV, Equipment Financing To Spur Zyoptix Wavefront LASIK Use
Bausch & Lomb will launch a TV ad campaign for the Zyoptix custom wavefront ablation system upon FDA approval by year-end, Senior VP and CFO Stephen McCluski said at the Bear Stearns annual healthcare conference in New York Sept. 9
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.